Lupus (SLE)
OMRF seeks healthy minority participants for one-time blood sample donation
Clinical Trials
For more information on any of the studies listed below, call (405) 271-7805 or email clinic@omrf.org.
Clarification of Abatacept Effects in SLE with Integrated Biologic and Clinical Approaches (The ABC Study), Protocol BMS-IM101-345 (ACTIVE)
OMRF Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence on Confounding Polypharmacy (The BLAST Study) (ACTIVE)
Predictors of Therapeutic Response in Lupus Nephritis (ACTIVE)
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE (the MEASURE trial), Protocol BMS IM101-636 (ACTIVE – Open to Enrollment/Accrual)
A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis, AUR-VCS-2016-02 (ACTIVE – Closed to Enrollment/Accrual)
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus, Protocol D3461C00009 (TULIP LTE) (ACTIVE – Closed to Enrollment/Accrual)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus, Protocol IM011021 (ACTIVE – Open to Enrollment/Accrual)
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus, Protocol TAK-079-2001 (ACTIVE – Temporarily Closed to Enrollment)
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis, Protocol IM011073 (ACTIVE – Temporarily Closed to Enrollment)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE-BRAVE), Protocol I4V-MC-JAIA (ACTIVE – Temporarily Closed to Enrollment)
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus, Protocol IM11074 (ACTIVE – Open to Enrollment/Accrual)
A Multi-Centre Long-Term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis, Protocol 209564 (ACTIVE – Open to Enrollment/Accrual)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus, Protocol SL0043 (ACTIVE – Open to Enrollment/Accrual)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis, Protocol CA41705 (ACTIVE – Open to Enrollment/Accrual)
Immunogenetic Studies of the De-identified Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (ACTIVE – Open to Enrollment/Accrual)
Antibody Mediated Spontaneous Abortion in Lupus Pregnancies (ACTIVE)
Genetic and Immunologic Determinants of Adverse Outcomes in Lupus Pregnancies (ACTIVE – Open to Enrollment/Accrual)
EISAI-Oklahoma Medical Research Foundation (OMRF) Collaboration on Systemic Lupus Erythematous Genetics (ACTIVE – Open to Enrollment/Accrual)
Dissecting Molecular Heterogeneity of SLE Patient Treatment Response (ACTIVE – Open to Enrollment/Accrual)
Registry for Atherosclerosis, Neuropsychiatric Disorders and Cancer Risks in SLE – The Systemic Lupus International Collaborating Clinics (SLICC) (ACTIVE – Closed to Enrollment/Accrual)
Pre-Clinical Studies to Identify SLE Therapeutic Targets (ACTIVE – Open to Enrollment/Accrual)
Understanding Early Events in Lupus to Aid in Prevention (ACTIVE)
Molecular Dissection of Disease Heterogeneity in Systemic Lupus Erythematosus (SLE) (ACTIVE – Open to Enrollment/Accrual)
Study of anti-Malarials in Incomplete Lupus Erythematosus (SMILE) (ACTIVE – Open to Enrollment/Accrual)
Granulopoiesis in Systemic Lupus Erythematosus (ACTIVE – Open to Enrollment/Accrual)
Contribution of Dysregulated Granulopoiesis to SLE Pathogenesis (ACTIVE – Open to Enrollment/Accrual)
Role of Dysregulated Myelopoiesis in SLE Pathogenesis (ACTIVE – Open to Enrollment/Accrual)
A Prospective Registry to Study Presentation, Clinical Course, Treatment Patterns, and Outcomes in Patients with Systemic Lupus Erythematosus (ACTIVE)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interests and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA (belimumab), Protocol HGS1006-C1124 (SABLE) (ACTIVE – Closed to Enrollment/Accrual)
Connecting People with Lupus to Improve Meaningful Benefits from Trials, the CLIMB study (ACTIVE – Open to Enrollment/Accrual)
Systemic Lupus: Improving the Rationale for Treatment Choices in a Heterogeneous Disease (ACTIVE – Open to Enrollment/Accrual)
Ascertaining Molecular Signatures of Active SLE (ACTIVE – Open to Enrollment/Accrual)
Systems Signatures of Preclinical Lupus in Autoantibody Positive Blood Relatives (ACTIVE – Open to Enrollment/Accrual)
Development of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE) (ACTIVE – Open to Enrollment/Accrual)
Using Circulating Progenitor Cells to Examine the Role of Stem Cell Factor (SCF) in SLE Pathogenesis (ACTIVE – Open to Enrollment/Accrual)
Algorithm Refinement to Predict Clinical Disease Flare through Longitudinal Assessment of Systemic Lupus Erythematosus Patients (ACTIVE – Open to Enrollment/Accrual)
Quantitative Analysis of Serum Autoantibody Repertoires in Systemic Lupus Erythematosus (ACTIVE – Open to Enrollment/Accrual)
